W. Schmidt

Considerations for toxicology studies of respiratory drug products.

A. S. Taylor, P. Andrews, J. Degeorge, 1997, Regulatory toxicology and pharmacology : RTP.

Regulatory considerations for preclinical development of anticancer drugs

Chang-Ho Ahn, P. Andrews, J. Degeorge, 1997, Cancer Chemotherapy and Pharmacology.

Approaches to the development and marketing approval of drugs that prevent cancer.

V. Steele, C. Boone, G. Kelloff, 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The Influence of Regulation on Toxicology

W. Schmidt, M. De, Owen G. McMaster, 2006 .

Guidance for development of chemopreventive agents

V. Steele, C. Boone, G. Kelloff, 1994, Journal of cellular biochemistry. Supplement.

A Systemic Exposure-Based Alternative to the Maximum Tolerated Dose for Carcinogenicity Studies of Human Therapeutics

J. Contrera, A. Jacobs, M. Mehta, 1995 .

Regulatory science: a special update from the United States Food and Drug Administration: Preclinical issues and status of investigation of botanical drug products in the United States.

H. Geyer, A. Atrakchi, T. Du, 2000, Toxicology letters.

Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents

R. Justice, J. Beitz, W. Schmidt, 1997, Journal of cellular biochemistry. Supplement.